Pictet Asset Management Holding SA boosted its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 15.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 227,732 shares of the company’s stock after purchasing an additional 30,834 shares during the quarter. Pictet Asset Management Holding SA owned about 0.39% of Harmony Biosciences worth $8,947,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Chase Investment Counsel Corp bought a new stake in shares of Harmony Biosciences in the 2nd quarter worth about $1,820,000. Canada Pension Plan Investment Board purchased a new stake in shares of Harmony Biosciences during the 2nd quarter valued at about $1,209,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Harmony Biosciences during the 2nd quarter valued at about $1,656,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Harmony Biosciences during the 2nd quarter valued at about $870,000. Finally, Aurora Investment Counsel bought a new position in shares of Harmony Biosciences in the 2nd quarter valued at about $2,372,000. Institutional investors own 86.23% of the company’s stock.
Analyst Upgrades and Downgrades
HRMY has been the subject of several recent research reports. Deutsche Bank reiterated a “hold” rating and issued a $42.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 1st. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Weiss Ratings downgraded Harmony Biosciences from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, November 9th. Oppenheimer restated an “outperform” rating on shares of Harmony Biosciences in a research report on Thursday, September 24th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Harmony Biosciences in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.00.
View Our Latest Research Report on HRMY
Key Harmony Biosciences News
These are some of the HRMY news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its 2028–2030 EPS forecasts, including 2028 to $6.06 from $5.81 and 2030 to $7.30 from $7.11, while retaining its “Buy” rating and $55 target. Article: Harmony Biosciences Stock Keeps Buy Rating at HC Wainwright
- Negative Sentiment: The analyst lowered estimates for several nearer-term periods: FY2026 EPS to $3.37 from $3.52, FY2027 to $4.50 from $4.69, and quarterly forecasts for Q4 2026 through Q4 2027. This broad downward revision signals a more cautious earnings outlook. Harmony Biosciences analyst information
- Negative Sentiment: Recent quarterly results also showed profit falling despite 12% sales growth; EPS and revenue came in below consensus, adding pressure to the near-term earnings picture. Article: Harmony Biosciences Profit Falls Despite 12% Sales Growth
Insider Buying and Selling at Harmony Biosciences
In other news, insider Kumar Budur sold 35,852 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the completion of the sale, the insider directly owned 13,115 shares of the company’s stock, valued at approximately $564,600.75. The trade was a 73.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 72,406 shares of company stock worth $3,108,520 in the last ninety days. 11.00% of the stock is currently owned by company insiders.
Harmony Biosciences Stock Performance
Shares of HRMY opened at $33.76 on Monday. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.90 and a twelve month high of $43.49. The company has a market cap of $1.98 billion, a P/E ratio of 11.18, a P/E/G ratio of 0.36 and a beta of 1.00. The company has a current ratio of 3.44, a quick ratio of 3.42 and a debt-to-equity ratio of 0.12. The company’s fifty day simple moving average is $38.65 and its 200-day simple moving average is $34.62.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.28). Harmony Biosciences had a return on equity of 18.55% and a net margin of 18.05%. The business had revenue of $268.92 million during the quarter, compared to analysts’ expectations of $272.05 million. During the same quarter in the previous year, the company posted $1.08 earnings per share. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 3.55 EPS for the current year.
About Harmony Biosciences
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.
Read More
- Five stocks we like better than Harmony Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
